IMCR vs UNH

Immunocore continues to demonstrate significant 10x potential, driven by its validated ImmTAX platform and first-in-class KIMMTRAK. The company's unique ability to target historically undruggable intracellular antigens offers a vast market opportunity across oncology and infectious diseases, especially with promising lead pipeline assets like PRAME showing continued progress. While success remains...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...